Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Prospective Cohort Study to Evaluate Safety of Remsima® Subcutaneous in Patients With Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis

NCT05866614 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.

NCT NCT05866614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05866614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Prospective Cohort Study to Evaluate Safety of Remsima® Subcutaneous in Patients With Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis
Lead sponsor
Celltrion
Phase
Observational
Overall status
Active, not recruiting
Start date
January 13, 2023
Completion date
March 31, 2027
Enrollment
881 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis